Skip to main content
. 2020 Sep 17;11(9):770. doi: 10.1038/s41419-020-02974-0

Fig. 1. GP2-treated mice are resistant to obesity-associated metabolic disorders.

Fig. 1

Six-week-old male mice were fed a high-fat diet for 8 weeks, and then treated with or without GP2-200 mg/kg/d for 5 weeks (n = 8–10). a Body weight changes in 32 days. b Body weight gain of mice after 32 days of GP2 treatment. c Fat mass and lean mass were assessed by NMR after 4 weeks of GP2 treatment. d Organ weight of mice treated with or without GP2. e Representative pictures of H&E staining of iWAT, eWAT, BAT and the liver at the end of dietary intervention. Scale bar = 100 μm. f Levels of hepatic TG in vehicle-treated and GP2-treated mice. g–j Mice were fasted for 6 h, and the fasting blood triglyceride (g), cholesterol (h), glucose (i) and insulin (j) levels of vehicle-treated mice and GP2-treated mice were measured. k, l Oral glucose tolerance test (OGTT, 2.0 g/kg) was conducted after three weeks treatment (k); the area under curve of glucose level in 90 min of the OGTT (l). The results are shown as the mean ± s.e.m., *P < 0.05, **P < 0.01 compared with vehicle.